Bank of New York Mellon Corp Raises Holdings in Humacyte, Inc. (NASDAQ:HUMA)

Bank of New York Mellon Corp increased its position in Humacyte, Inc. (NASDAQ:HUMA) by 62.7% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 254,013 shares of the company’s stock after purchasing an additional 97,931 shares during the period. Bank of New York Mellon Corp owned 0.21% of Humacyte worth $1,219,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Victory Capital Management Inc. purchased a new stake in Humacyte in the fourth quarter valued at approximately $29,000. China Universal Asset Management Co. Ltd. boosted its stake in Humacyte by 65.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 19,883 shares of the company’s stock worth $62,000 after purchasing an additional 7,897 shares during the period. Hartline Investment Corp purchased a new position in Humacyte during the 1st quarter worth $70,000. Anson Funds Management LP purchased a new position in Humacyte during the 1st quarter worth $156,000. Finally, Virtu Financial LLC purchased a new stake in shares of Humacyte in the first quarter valued at about $197,000. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte Stock Performance

NASDAQ:HUMA opened at $5.20 on Friday. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.61. Humacyte, Inc. has a fifty-two week low of $1.96 and a fifty-two week high of $9.97. The firm’s fifty day simple moving average is $6.85 and its 200-day simple moving average is $5.58. The stock has a market cap of $619.24 million, a PE ratio of -5.20 and a beta of 1.47.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). Analysts expect that Humacyte, Inc. will post -1.09 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Humacyte news, CEO Laura E. Niklason sold 277,090 shares of the company’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $6.47, for a total value of $1,792,772.30. Following the sale, the chief executive officer now owns 4,029,374 shares of the company’s stock, valued at $26,070,049.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Humacyte news, CEO Laura E. Niklason sold 277,090 shares of the company’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $6.47, for a total value of $1,792,772.30. Following the sale, the chief executive officer now owns 4,029,374 shares of the company’s stock, valued at $26,070,049.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Brady W. Dougan sold 252,676 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the transaction, the director now directly owns 4,306,464 shares of the company’s stock, valued at $28,896,373.44. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,084,153 shares of company stock valued at $6,869,996. 23.10% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. EF Hutton Acquisition Co. I raised Humacyte to a “strong-buy” rating in a report on Monday, September 9th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 target price on shares of Humacyte in a research note on Friday. Benchmark restated a “buy” rating and set a $15.00 price target on shares of Humacyte in a research note on Thursday, September 5th. Finally, BTIG Research lifted their price objective on shares of Humacyte from $8.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, July 15th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $9.80.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.